Analysis
Latigo Biotherapeutics set terms for its Nasdaq IPO, offering 16 million shares at $16 to $18 each to raise up to $272 million under the ticker LTGO, according to Renaissance Capital. At the midpoint of that range, the Thousand Oaks, California company would carry a fully diluted market value near $1.2 billion.
A Direct Rival to an Approved Drug
Latigo's lead candidate, LTG-001, is an oral Nav1.8 sodium channel inhibitor targeting moderate to severe acute pain, including postoperative pain -- the same non-opioid mechanism behind Vertex's already-approved Journax. The company recently reported positive topline data from a 343-patient abdominoplasty trial, meeting its primary endpoint against placebo, with a Phase 3 bunionectomy trial and an open-label safety study both planned for the second half of 2026.
The Cap Table Behind the Listing
Latigo has raised $321.5 million privately since its 2018 founding, with backing from Westlake Village BioPartners, Foresite Capital, 5AM Ventures and Blue Owl Capital -- a well-capitalized biotech cap table heading into a public listing that will directly test investor appetite for a company competing against a drug class that's already commercially validated rather than pioneering an unproven mechanism.
What to watch: how LTGO prices relative to its $16-18 range and trades in its first weeks, and whether its second candidate, LTG-321, targeting chronic musculoskeletal pain, produces Phase 2 data that broadens the investment case beyond the acute-pain comparison to Journax.